Premium Nahrungsergänzungsmittel | artgerecht

Anti-dsDNA Antibodies: Meaning & Diagnosis

Anti-dsDNA antibodies are autoantibodies directed against the body's own DNA. They are a key laboratory marker for systemic lupus erythematosus (SLE).

Regular tips about health Regular tips about health

Things worth knowing about "Anti-dsDNA antibodies"

Anti-dsDNA antibodies are autoantibodies directed against the body's own DNA. They are a key laboratory marker for systemic lupus erythematosus (SLE).

What are Anti-dsDNA Antibodies?

Anti-dsDNA antibodies (antibodies against double-stranded DNA) are autoantibodies – meaning antibodies that the immune system mistakenly produces against the body's own structures. In this case, they target double-stranded deoxyribonucleic acid (dsDNA), the fundamental building block of human genetic material. Their detection in the blood is a clinically significant diagnostic indicator for certain autoimmune diseases, most notably systemic lupus erythematosus (SLE).

Clinical Significance

Anti-dsDNA antibodies are among the most important laboratory parameters in rheumatology and immunology. They are included in the official SLE classification criteria (ACR/EULAR criteria) and serve both for diagnosis and for monitoring disease activity over time.

Specificity for SLE: Anti-dsDNA antibodies are highly specific for SLE. They are found in approximately 70–80% of SLE patients but are rarely detected in healthy individuals or in other diseases.
Disease activity: The antibody titer (concentration) often correlates with disease activity. A rising titer may precede or accompany a lupus flare.
Lupus nephritis: There is a particularly strong association with lupus nephritis, a kidney inflammation caused by SLE. High titers are a risk factor for this serious organ complication.

How Do Anti-dsDNA Antibodies Develop?

When immune regulation is disrupted, the immune system no longer recognizes the body's own DNA as "self" and produces antibodies against it. These antibodies can form so-called immune complexes together with DNA fragments, which deposit in tissues – particularly in the kidneys, joints, and blood vessels – triggering inflammatory reactions. The exact causes of this immune system malfunction are not yet fully understood; genetic factors, hormonal influences, and environmental triggers (e.g., UV light, infections) all play a role.

Diagnosis: How Are the Antibodies Detected?

Anti-dsDNA antibodies are detected from a simple blood sample. Several testing methods are available:

ELISA (Enzyme-Linked Immunosorbent Assay): A widely used, standardized method for the quantitative determination of antibody titers.
Crithidia luciliae Immunofluorescence Test (CLIFT): Considered highly specific for anti-dsDNA antibodies. The antibodies are visualized by their binding to the kinetoplast of the single-celled organism Crithidia luciliae, which contains pure dsDNA.
Farr Assay (Radioimmunoassay): An older, highly sensitive method that is less commonly used today.

Results are reported as positive or negative, and quantitatively as a titer or in international units (IU/ml). Interpretation should always be made in the clinical context and in conjunction with other laboratory values (e.g., complement C3/C4, ANA).

Occurrence in Other Conditions

Although anti-dsDNA antibodies are considered highly specific for SLE, they can also be detected at low titers in other conditions, including:

Drug-induced lupus (e.g., caused by hydralazine, procainamide)
Other connective tissue diseases (e.g., Sjogren's syndrome, rheumatoid arthritis)
Chronic inflammatory liver diseases (e.g., autoimmune hepatitis)
Infectious diseases (rarely, usually low titers)

Treatment and Disease Monitoring

Anti-dsDNA antibodies themselves are not directly treated. Therapy is directed at the underlying disease, i.e., SLE. Medications used include hydroxychloroquine, corticosteroids, immunosuppressants (e.g., azathioprine, mycophenolate mofetil), and for severe cases biologics such as belimumab. Regular monitoring of antibody titers helps to detect disease flares early and to adjust therapy accordingly.

References

Hochberg MC et al. – Rheumatology, 7th Edition. Elsevier, 2019.
Aringer M et al. – 2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis & Rheumatology, 2019. DOI: 10.1002/art.40930.
Pisetsky DS – Anti-DNA antibodies – quintessential biomarkers of SLE. Nature Reviews Rheumatology, 2016. DOI: 10.1038/nrrheum.2016.51.

Building Blocks for a Healthy Life

As an integrated manufacturer, we develop & produce evidence-based, patented, and non-patented formulations. We work exclusively with plant and natural extracts according to the strictest purity & quality standards.
The combination of science & modern technology with the laws of nature creates solutions consistently tailored to humans – for the highest good: health.